# Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.

> **NCT00323804** · PHASE2,PHASE3 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 372 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Liver Fibrosis

## Interventions

- **BIOLOGICAL:** Peginterferon alfa-2b
- **DRUG:** Ribavirin
- **DRUG:** Ribavirin-Placebo

## Key facts

- **NCT ID:** NCT00323804
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2013-02
- **Final completion:** 2013-03
- **Target enrollment:** 372 (ACTUAL)
- **Last updated:** 2014-09-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323804, "Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00323804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*